Yahoo Finance • yesterday
We recently published 10 Small Stocks with Mighty Gains. Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the top-performing stocks on Wednesday. Sana Biotechnology soared by 14.53 percent on Wednesday to finish at $4.02 apiece as investo... Full story
Yahoo Finance • 5 days ago
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor... Full story
Yahoo Finance • 10 days ago
Issued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies ra... Full story
Yahoo Finance • 11 days ago
Sana Biotechnology Inc. (NASDAQ:SANA) is a must-buy penny stock according to analysts. On November 7, Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Sana Biotechnology (NASDAQ: SANA) and set a price target of... Full story
Yahoo Finance • 29 days ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • last month
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Dragon Claws/iStock via Getty Images Shares of Sana Biotechnology (NASDAQ:SANA [https://seekingalpha.co... Full story
Yahoo Finance • 2 months ago
We came across a bullish thesis on TruBridge, Inc. (TBRG) on Negócios pelo Mundo’s Substack by Leo Caroli. In this article, we will summarize the bulls’ thesis on TBRG. TruBridge, Inc. (TBRG)'s share was trading at $21.79 as of September 1... Full story
Yahoo Finance • 3 months ago
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the biop... Full story
Yahoo Finance • 3 months ago
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor... Full story
Yahoo Finance • 3 months ago
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 share... Full story
Yahoo Finance • 4 months ago
SEATTLE - Sana Biotechnology, Inc. (NASDAQ:SANA), whose stock has surged over 160% year-to-date with a current market capitalization of approximately $959 million, has priced its underwritten public offering of 20,895,522 shares of common... Full story
Yahoo Finance • 4 months ago
* Sana Biotechnology (NASDAQ:SANA [https://seekingalpha.com/symbol/SANA]) priced [https://seekingalpha.com/pr/20192464-sana-biotechnology-announces-pricing-of-public-offering] its underwritten public offering of ~20.89M shares at $3.35 p... Full story
Yahoo Finance • 4 months ago
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public off... Full story
Yahoo Finance • 4 months ago
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public o... Full story
Yahoo Finance • 4 months ago
Seres Therapeutics, Inc. Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to... Full story
Yahoo Finance • 4 months ago
Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Tran... Full story
Yahoo Finance • 4 months ago
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Best American Penny Stocks to Buy According to Analysts.On July 2, Citi analyst Samantha Semenkow maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) with a price target of... Full story
Yahoo Finance • 5 months ago
Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data... Full story
Yahoo Finance • 5 months ago
Investing.com - Morgan Stanley has initiated coverage on Sana Biotechnology (NASDAQ:SANA) with an Overweight rating and a $12.00 price target, joining a broader analyst consensus that sees significant upside potential. The stock, which h... Full story
Yahoo Finance • 5 months ago
Sana Biotechnology , Inc. (NASDAQ:SANA), a clinical-stage biotechnology company with a market capitalization of $645 million, has been making significant strides in the field of cell therapy. According to InvestingPro data, the stock has s... Full story